205 related articles for article (PubMed ID: 29594036)
1. Dosimetric Impact of a Tumor Treating Fields Device for Glioblastoma Patients Undergoing Simultaneous Radiation Therapy.
Li T; Shukla G; Peng C; Lockamy V; Liu H; Shi W
Front Oncol; 2018; 8():51. PubMed ID: 29594036
[TBL] [Abstract][Full Text] [Related]
2. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Treating Field Arrays Do Not Reduce Target Volume Coverage for Glioblastoma Radiation Therapy.
Stachelek GC; Grimm J; Moore J; Huang E; Spoleti N; Redmond KJ; Lim M; Bettegowda C; Kleinberg L
Adv Radiat Oncol; 2020; 5(1):62-69. PubMed ID: 32051891
[TBL] [Abstract][Full Text] [Related]
4. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
[TBL] [Abstract][Full Text] [Related]
5. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma.
Miller R; Song A; Ali A; Niazi M; Bar-Ad V; Martinez N; Glass J; Alnahhas I; Andrews D; Judy K; Evans J; Farrell C; Werner-Wasik M; Chervoneva I; Ly M; Palmer J; Liu H; Shi W
Front Oncol; 2022; 12():896246. PubMed ID: 35574391
[TBL] [Abstract][Full Text] [Related]
6. Targeting Accuracy Considerations for Simultaneous Tumor Treating Fields Antimitotic Therapy During Robotic Hypofractionated Radiation Therapy.
Biswas S; Kapitanova I; Divekar S; Grimm J; Butterwick IJ; Garren D; Kleinberg LR; Redmond KJ; Lacroix M; Mahadevan A; Forster KM
Technol Cancer Res Treat; 2021; 20():15330338211039135. PubMed ID: 34632866
[No Abstract] [Full Text] [Related]
7. Dosimetric impact of the positioning variation of tumor treating field electrodes in the PriCoTTF-phase I/II trial.
Nour Y; Pöttgen C; Kebir S; Lazaridis L; Lüdemann L; Guberina M; Gauler T; Scheffler B; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Glas M; Lübcke W; Stuschke M; Guberina N
J Appl Clin Med Phys; 2021 Jan; 22(1):242-250. PubMed ID: 33389825
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas - a planning study.
Straube C; Oechsner M; Kampfer S; Scharl S; Schmidt-Graf F; Wilkens JJ; Combs SE
Radiat Oncol; 2018 Feb; 13(1):31. PubMed ID: 29471879
[TBL] [Abstract][Full Text] [Related]
9. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells.
Giladi M; Munster M; Schneiderman RS; Voloshin T; Porat Y; Blat R; Zielinska-Chomej K; Hååg P; Bomzon Z; Kirson ED; Weinberg U; Viktorsson K; Lewensohn R; Palti Y
Radiat Oncol; 2017 Dec; 12(1):206. PubMed ID: 29284495
[TBL] [Abstract][Full Text] [Related]
10. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric study of uniform scanning proton therapy planning for prostate cancer patients with a metal hip prosthesis, and comparison with volumetric-modulated arc therapy.
Rana S; Cheng C; Zheng Y; Hsi W; Zeidan O; Schreuder N; Vargas C; Larson G
J Appl Clin Med Phys; 2014 May; 15(3):4611. PubMed ID: 24892333
[TBL] [Abstract][Full Text] [Related]
12. Tumor treating fields with radiation for glioblastoma: a narrative review.
Miller R; Niazi M; Russial O; Poiset S; Shi W
Chin Clin Oncol; 2022 Oct; 11(5):40. PubMed ID: 36336899
[TBL] [Abstract][Full Text] [Related]
13. Intensity-modulated radiotherapy, coplanar volumetric-modulated arc, therapy, and noncoplanar volumetric-modulated arc therapy in, glioblastoma: A dosimetric comparison.
Hou Y; Zhang Y; Liu Z; Yv L; Liu K; Tian X; Lv Y
Clin Neurol Neurosurg; 2019 Dec; 187():105573. PubMed ID: 31706107
[TBL] [Abstract][Full Text] [Related]
14. Plan quality and delivery time comparisons between volumetric modulated arc therapy and intensity modulated radiation therapy for scalp angiosarcoma: A planning study.
Kai Y; Toya R; Saito T; Kuraoka A; Shimohigashi Y; Nakaguchi Y; Maruyama M; Murakami R; Yamashita Y; Oya N
J Med Radiat Sci; 2018 Mar; 65(1):39-47. PubMed ID: 28755441
[TBL] [Abstract][Full Text] [Related]
15. Volumetric-modulated arc therapy (VMAT) for whole brain radiotherapy: not only for hippocampal sparing, but also for reduction of dose to organs at risk.
Sood S; Pokhrel D; McClinton C; Lominska C; Badkul R; Jiang H; Wang F
Med Dosim; 2017 Winter; 42(4):375-383. PubMed ID: 28822604
[TBL] [Abstract][Full Text] [Related]
16. Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma.
Lacouture ME; Anadkat MJ; Ballo MT; Iwamoto F; Jeyapalan SA; La Rocca RV; Schwartz M; Serventi JN; Glas M
Front Oncol; 2020; 10():1045. PubMed ID: 32850308
[No Abstract] [Full Text] [Related]
17. Importance of electrode position for the distribution of tumor treating fields (TTFields) in a human brain. Identification of effective layouts through systematic analysis of array positions for multiple tumor locations.
Korshoej AR; Hansen FL; Mikic N; von Oettingen G; Sørensen JCH; Thielscher A
PLoS One; 2018; 13(8):e0201957. PubMed ID: 30133493
[TBL] [Abstract][Full Text] [Related]
18. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.
Connelly J; Hormigo A; Mohilie N; Hu J; Chaudhry A; Blondin N
BMC Cancer; 2016 Nov; 16(1):842. PubMed ID: 27809808
[TBL] [Abstract][Full Text] [Related]
19. Investigation of pulsed IMRT and VMAT for re-irradiation treatments: dosimetric and delivery feasibilities.
Lin MH; Price RA; Li J; Kang S; Li J; Ma CM
Phys Med Biol; 2013 Nov; 58(22):8179-96. PubMed ID: 24200917
[TBL] [Abstract][Full Text] [Related]
20. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
